Key result
SUR2A emerges as a plausible effector of cardioprotection against ischemia-reperfusion injury, pending further validation.
Why the study?
Translating experimental cardioprotection into effective clinical therapies remains limited. While research has largely focused on upstream signaling networks, downstream effectors determining myocardial stress resistance, such as SUR2A, have received comparatively less attention.
This review highlights sulfonylurea receptor 2A (SUR2A), the regulatory subunit of the cardiac sarcolemmal KATP channel, as a plausible but incompletely validated downstream adaptive effector linking metabolic signaling to cardioprotection against ischemia-reperfusion injury.
Answers are grounded in this paper and cite their sources.
SUR2A shows no clinical role yet; leaves open its therapeutic targeting pending human validation and resolution of paradoxes.
Despite decades of intensive investigation, translation of experimental cardioprotection into effective clinical therapies remains limited. Research has largely focused on upstream signaling networks, including RISK, SAFE, NO/cGMP/PKG and AMPK, whereas the downstream effectors that determine myocardial stress resistance have received comparatively less attention. This review examines sulfonylurea receptor 2A (SUR2A), the regulatory subunit of the cardiac sarcolemmal ATP-sensitive potassium (KATP) channel, as a potential adaptive effector of cardioprotection. Experimental evidence indicates that SUR2A abundance can limit functional KATP-channel assembly and that moderate increases in SUR2A enhance resistance to metabolic stress and ischemia–reperfusion injury. SUR2A expression is dynamically regulated by hypoxia, AMPK, ERK1/2, PI3K/Akt, estrogen and nicotinamide, providing potential links between established cardioprotective signaling and sustained channel remodeling. However, paradoxical protection after SUR2 deletion, limited isoform-specific loss-of-function studies and sparse human validation indicate that SUR2A cannot yet be regarded as an established common effector. We propose an effector-centric framework in which SUR2A represents a plausible, but incompletely validated, convergence point linking metabolic signaling to electrical and energetic adaptation, and identify the experiments required to test its translational relevance.
No takes yet. Share an insight, caveat, or question.
Aleksandar Jovanović (2026) conducted a review in Myocardial stress and ischemia-reperfusion injury. Sulfonylurea receptor 2A (SUR2A) modulation was evaluated on Resistance to metabolic stress and ischemia-reperfusion injury. SUR2A acts as a plausible adaptive effector of cardioprotection against ischemia-reperfusion injury, though validation remains incomplete.
Synapse has enriched 10 related papers. Consider them for comparative context: